Full Title
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (AALL2131) (CIRB)Purpose
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
Blinatumomab is a bispecific antibody. It binds to two different proteins: one on the surface of cancer cells and another on the surface of immune cells. Blinatumomab may strengthen the immune system’s ability to fight cancer cells by activating immune cells to destroy the tumor. It is given intravenously (by vein).
Dasatinib and imatinib work by blocking an abnormal protein that signals cancer cells to multiply. This may help keep cancer cells from growing. Dasatinib and imatinib are taken orally (by mouth).
Blinatumomab and dasatinib or imatinib with chemotherapy may work better for people with B-ALL than dasatinib or imatinib with chemotherapy.
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have Ph+ or ABL-class Ph-like B-ALL.
- Be age 1-22.
Contact
For more information about this study or to see if you or your child can join, please call 833-MSK-KIDS.